/EIN News/ -- Dublin, Jan. 28, 2019 (GLOBE NEWSWIRE) -- The "Mucopolysaccharidosis Type I (Hurler Syndrome) R&D Pipeline Analysis Report, H2-2018" drug pipelines has been added to ResearchAndMarkets.com's offering.

The Mucopolysaccharidosis Type I (Hurler Syndrome) pipeline guide presents complete overview of drugs currently being developed for Mucopolysaccharidosis Type I (Hurler Syndrome). The pipeline review provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials).

Drug development phase, current stage, mechanism of action, route of administration, orphan drug/ fast track/ other designations, drug class are provided for each of the Mucopolysaccharidosis Type I (Hurler Syndrome) pipeline candidate.
Research and Development progress along with latest news related to each of the Mucopolysaccharidosis Type I (Hurler Syndrome) pipeline candidates is included.

Major companies participating in therapeutic development of Mucopolysaccharidosis Type I (Hurler Syndrome) are included in this pipeline report. Company wise pre clinical and clinical products along with details of drug originator, co developers/ licensors are provided.

Amid strong interest for cure of Mucopolysaccharidosis Type I (Hurler Syndrome) from companies and institutes, the current research work serves as a reliable and comprehensive source of information of global Mucopolysaccharidosis Type I (Hurler Syndrome) clinical and pre clinical products.

The report assists in identifying potential upcoming companies and drugs in Mucopolysaccharidosis Type I (Hurler Syndrome) pipeline market along with progress of each drug. It also enables users to formulate effective strategies to stay ahead of competition.

Key Topics Covered:

I. Key Findings

1. Companies Investing in Mucopolysaccharidosis Type I (Hurler Syndrome) Pipeline include
Number of Companies with Mucopolysaccharidosis Type I (Hurler Syndrome) projects in pre clinical Development
Number of Companies with Mucopolysaccharidosis Type I (Hurler Syndrome) projects in Clinical Development
Mucopolysaccharidosis Type I (Hurler Syndrome) Pipeline Companies based in Americas
Mucopolysaccharidosis Type I (Hurler Syndrome) Pipeline Companies based in Europe
Mucopolysaccharidosis Type I (Hurler Syndrome) Pipeline Companies based in Asia Pacific
Mucopolysaccharidosis Type I (Hurler Syndrome) Pipeline Companies based in Rest of the World

2. Pipeline Candidates include
Mucopolysaccharidosis Type I (Hurler Syndrome) Pipeline Agents in pre clinical/ Discovery stage of Development
Mucopolysaccharidosis Type I (Hurler Syndrome) Pipeline Agents in Clinical Development stage
Mucopolysaccharidosis Type I (Hurler Syndrome) Pipeline Therapeutic Compounds received special status
Mechanism of Action of most pipeline Drugs
Small molecules among the Mucopolysaccharidosis Type I (Hurler Syndrome) Pipeline agents

II. Insights into Mucopolysaccharidosis Type I (Hurler Syndrome) Pipeline -

1. Disease Overview
Introduction to Mucopolysaccharidosis Type I (Hurler Syndrome)
Symptoms and Causes of Mucopolysaccharidosis Type I (Hurler Syndrome)
Treatment or Prevention Options for Mucopolysaccharidosis Type I (Hurler Syndrome)
Other Details
2. Phase wise Pipeline Compounds
Mucopolysaccharidosis Type I (Hurler Syndrome) Pipeline Pre Clinical/ Discovery stage Drugs
Mucopolysaccharidosis Type I (Hurler Syndrome) Pipeline Phase 1 stage Drugs
Mucopolysaccharidosis Type I (Hurler Syndrome) Pipeline Phase 2 stage Drugs
Mucopolysaccharidosis Type I (Hurler Syndrome) Pipeline Phase 3 stage Drugs
Mucopolysaccharidosis Type I (Hurler Syndrome) Pipeline Pre Registration stage Drugs
3. Company wise Mucopolysaccharidosis Type I (Hurler Syndrome) Pipeline Compounds
4. Mucopolysaccharidosis Type I (Hurler Syndrome) Pipeline by Mechanism of Action

III. Mucopolysaccharidosis Type I (Hurler Syndrome) Pipeline Compound Details

Drug Details

1. Snapshot
Name of the Therapeutic Agent
Originator
Developing Company
Co Developer/ License Partner
Orphan Drug / Fast Track/ Designation
Development Phase
2. Drug Overview
3. Mechanism of Action
4. Current Status
5. Clinical Trial Details

IV. Mucopolysaccharidosis Type I (Hurler Syndrome) Pipeline Company Briefs

V. Latest News and Developments in Global Mucopolysaccharidosis Type I (Hurler Syndrome) Pipeline Market

VI. Appendix

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/2bm8n6/mucopolysaccharido?w=12

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

CONTACT: ResearchAndMarkets.com
         Laura Wood, Senior Press Manager
         press@researchandmarkets.com
         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900
Related Topics: Immune Disorders Drugs